01 September 2014
Alpharetta, GA (September 2, 2014) – Clearside Biomedical, Inc., today announced the closing of a $16 million Series B financing. The financing included new investor RusnanoMedInvest (RMI) and existing investors Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund.
Clearside expects to use proceeds from this financing to fund continued development of Clearside’s proprietary suprachoroidal space (SCS) drug administration and advance its CLS-1001 and CLS-1003 programs into Phase 2 trials by the end of 2014.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye. Clearside’s product candidates focus on diseases affecting the retina and the choroid, especially diseases associated with macular edema, and are injected non-surgically into the suprachoroidal space with Clearside’s proprietary microinjector. Visit www.clearsidebio.com for more information.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024